Enhanced immunogenicity of a novel Stx2Am-Stx1B fusion protein in a mice model of enterohemorrhagic Escherichia coli O157:H7 infection

Vaccine

Volumn 29, Issue 5, 2011, Pages 946-952

  Cai, Kun ^a   Gao, Xiang ^a   Li, Tao ^a   Wang, Qin ^a   Hou, Xiaojun ^a   Tu, Wei ^a   Xiao, Le ^a   Tian, Maoren ^a   Liu, Yuenan ^a   Wang, Hui ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Cross protection; Cytokine; Immunogenicity; Shiga toxin 1B subunit; Shiga toxin 2A subunit

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; INTERLEUKIN 10; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; PROTEIN SAMB; SHIGA TOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGENICITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; FEMALE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; RECOMBINANT FUSION PROTEINS; SHIGA TOXIN 1; SHIGA TOXIN 2;

EID: 78751579157     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.035     Document Type: Article

References (44)

1. Karmali M.A. Infection by Shiga toxin-producing Escherichia coli: an overview. Mol Biotechnol 2004, 26(2):117-122.
2. Tarr P.I., Gordon C.A., Chandler W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005, 365(9464):1073-1086.
3. Cleary T.G. The role of Shiga-toxin-producing Escherichia coli in hemorrhagic colitis and hemolytic uremic syndrome. Semin Pediatr Infect Dis 2004, 15(4):260-265.
4. Centers for Disease Control and Prevention. Addressing emergine infectious disease threats: a prevention strategy for the United States (executive summary). Morb Mortal Wkly Rep 1994;43(RR-5):1-18.
5. Paton J.C., Paton A.W. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998, 11(3):450-479.
6. Dean-Nystrom E.A., Gansheroff L.J., Mills M., Moon H.W., O'Brien A.D. Vaccination of pregnant dams with intimin(O157) protects suckling piglets from Escherichia coli O157:H7 infection. Infect Immun 2002, 70(5):2414-2418.
7. Beatty M.E., Bopp C.A., Wells J.G., Greene K.D., Puhr N.D., Mintz E.D. Enterotoxin-producing Escherichia coli O169:H41, United States. Emerg Infect Dis 2004, 10(3):518-521.
8. Fraser M.E., Chernaia M.M., Kozlov Y.V., James M.N. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 A resolution. Nat Struct Biol 1994, 1(1):59-64.
9. Fraser M.E., Fujinaga M., Cherney M.M., Melton-Celsa A.R., Twiddy E.M., O'Brien A.D., et al. Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J Biol Chem 2004, 279(26):27511-27517.
10. Furutani M., Ito K., Oku Y., Takeda Y., Igarashi K. Demonstration of RNA N-glycosidase activity of a Vero toxin (VT2 variant) produced by Escherichia coli O91:H21 from a patient with the hemolytic uremic syndrome. Microbiol Immunol 1990, 34(4):387-392.
11. Donohue-Rolfe A., Jacewicz M., Keusch G.T. Isolation and characterization of functional Shiga toxin subunits and renatured holotoxin. Mol Microbiol 1989, 3(9):1231-1236.
12. Jacewicz M., Clausen H., Nudelman E., Donohue-Rolfe A., Keusch G.T. Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J Exp Med 1986, 163(6):1391-1404.
13. Kaper J.B., O'Brien A.D. Escherichia coli O157:H7 and other shiga toxin-producing E. coli strains 1998, ASM Press, Washington, DC.
14. Acheson D.W., De Breucker S.A., Jacewicz M., Lincicome L.L., Donohue-Rolfe A., Kane A.V., et al. Expression and purification of Shiga-like toxin II B subunits. Infect Immun 1995, 63(1):301-308.
15. Strockbine N.A., Marques L.R., Newland J.W., Smith H.W., Holmes R.K., O'Brien A.D. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect Immun 1981, 53(1):135-140.
16. Downes F.P., Barrett T.J., Green J.H., Aloisio C.H., Spika J.S., Strockbine N.A., et al. Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies. Infect Immun 1988, 56(8):1926-1933.
17. Wadolkowski E.A., Sung L.M., Burris J.A., Samuel J.E., O'Brien A.D. Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. Infect Immun 1990, 58(12):3959-3965.
18. Wen S.X., Teel L.D., Judge N.A., O'Brien A.D. Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine 2006, 24(8):1142-1148.
19. Bielaszewska M., Clarke I., Karmali M.A., Petric M. Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits. Infect Immun 1997, 65(7):2509-2516.
20. Ludwig K., Karmali M.A., Smith C.R., Petric M. Cross-protection against challenge by intravenous Escherichia coli verocytotoxin 1 (VT1) in rabbits immunized with VT2 toxoid. Can J Microbiol 2002, 48(1):99-103.
21. Metz B., Jiskoot W., Hennink W.E., Crommelin D.J., Kersten G.F. Physicochemical and immunochemical techniques predict the quality of diphtheria toxoid vaccines. Vaccine 2003, 22(2):156-167.
22. Gordon V.M., Whipp S.C., Moon H.W., O'Brien A.D., Samuel J.E. An enzymatic mutant of Shiga-like toxin II variant is a vaccine candidate for edema disease of swine. Infect Immun 1992, 60(2):485-490.
23. Smith M.J., Teel L.D., Carvalho H.M., Melton-Celsa A.R., O'Brien A.D. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 2006, 24(19):4122-4129.
24. Nutikka A., Binning-Boyd B., Lingwood C.A. Methods for purification of shiga toxin 1. E. coli: Shiga toxin methods and protocoles 2002, 189-196. Humana Press, New Jersey. D. Philpott, F. Ebel (Eds.).
25. Tu W., Cai K., Gao X., Xiao L., Chen R., Shi J., et al. Improved production of holotoxin Stx2 with biological activities by using a single-promoter vector and an auto-induction expression system. Protein Expr Purif 2009, 67(2):169-174.
26. Boyd B., Richardson S., Gariepy J. Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter action of the toxin. Infect Immun 1991, 59(3):750-757.
27. Acheson D.W., Levine M.M., Kaper J.B., Keusch G.T. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infect Immun 1996, 64(1):355-357.
28. Butterton J.R., Ryan E.T., Acheson D.W., Calderwood S.B. Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains. Infect Immun 1997, 65(6):2127-2135.
29. Marcato P., Mulvey G., Read R.J., Vander Helm K., Nation P.N., Armstrong G.D. Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. J Infect Dis 2001, 183(3):435-443.
30. Gao X., Cai K., Shi J., Liu H., Hou X., Tu W., et al. Immunogenicity of a novel Stx2B-Stx1B fusion protein in a mice model of Enterohemorrhagic Escherichia coli O157:H7 infection. Vaccine 2009, 27(14):2070-2076.
31. Boerlin P., McEwen S.A., Boerlin-Petzold F., Wilson J.B., Johnson R.P., Gyles C.L. Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol 1999, 37(3):497-503.
32. Kleanthous H., Smith H.R., Scotland S.M., Gross R.J., Rowe B., Taylor C.M., et al. Haemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. Part 2: microbiological aspects. Arch Dis Child 1990, 65(7):722-727.
33. Ostroff S.M., Tarr P.I., Neill M.A., Lewis J.H., Hargrett-Bean N., Kobayashi J.M. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis 1989, 160(6):994-998.
34. Ohmura M., Yamamoto M., Tomiyama-Miyaji C., Yuki Y., Takeda Y., Kiyono H. Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation. Infect Immun 2005, 73(7):4088-4097.
35. Lindgren S.W., Melton A.R., O'Brien A.D. Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model. Infect Immun 1993, 61(9):3832-3842.
36. Haddad J.E., Jackson M.P. Identification of the Shiga toxin A-subunit residues required for holotoxin assembly. J Bacteriol 1993, 175(23):7652-7657.
37. Deresiewicz R.L., Calderwood S.B., Robertus J.D., Collier R.J. Mutations affecting the activity of the Shiga-like toxin I A-chain. Biochemistry 1992, 31(12):3272-3280.
38. Deresiewicz R.L., Austin P.R., Hovde C.J. The role of tyrosine-114 in the enzymatic activity of the Shiga-like toxin I A-chain. Mol Gen Genet 1993, 241(3-4):467-473.
39. Hovde C.J., Calderwood S.B., Mekalanos J.J., Collier R.J. Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I. Proc Natl Acad Sci USA 1988, 85(8):2568-2572.
40. Jackson M.P., Deresiewicz R.L., Calderwood S.B. Mutational analysis of the Shiga toxin and Shiga-like toxin II enzymatic subunits. J Bacteriol 1990, 172(6):3346-3350.
41. Yamasaki S., Furutani M., Ito K., Igarashi K., Nishibuchi M., Takeda Y. Importance of arginine at position 170 of the A subunit of Vero toxin 1 produced by enterohemorrhagic Escherichia coli for toxin activity. Microb Pathog 1991, 11(1):1-9.
42. Ishikawa S., Kawahara K., Kagami Y., Isshiki Y., Kaneko A., Matsui H., et al. Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1. Infect Immunol 2003, 71(6):3235-3239.
43. Turner D.J., Ritter M.A., George A.J. Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology. J Immunol Methods 1997, 205(1):43-54.
44. Chen R., Shi J., Cai K., Tu W., Hou X., Liu H., et al. Improved soluble expression and characterization of the Hc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli by using a PCR-synthesized gene and a Trx co-expression strain. Protein Expr Purif 2010, 71(1):79-84.